Understanding the genetic basis of HIV-1 drug resistance is essential for antiretroviral drug development. We analyzed drug resistant mutations in HIV-1 protease and reverse transcriptase under 18 drug treatments. The analysis is challenging because there is a large number of possible mutation combinations that may jointly affect drug resistance. The mutations are also strongly correlated, imposing inference difficulties such as multi-colinearity issues. We applied a novel Bayesian algorithm to the drug resistance data. Our method efficiently identified clusters of mutations in HIV-1 protease and reverse transcriptase that are strongly and directly associated with drug resistance. In addition to marginal associations, we detected strong interactions among mutations at distant protein locations. Most identified protein positions are crossresistant to several drugs of the same types. The effects of interactions are mostly negative, suggesting a threshold mechanism for the genetics underlying HIV drug resistance. Our method is among the first to produce detailed structures of marginal and interactive associations in HIV-1 drug resistance studies, and is generally suitable for detecting high-order interactions in large-scale datasets with complex dependencies.
INTRODUCTION
Human Immunodeficiency Virus (HIV) is a retrovirus causing the acquired immunodeficiency syndrome (AIDS). There are two major types of HIV. HIV-1 is the most common strain of the virus that has caused global HIV infection, which is the main therapeutic target of interest. HIV-2, on the other hand, has relatively lower infectivity and is mainly confined within western Africa. Upon entry into the target cell, the viral RNA genome is reverse transcribed into double-stranded DNA. The resulting viral DNA is then imported into the cell nucleus and integrated into the host genome to begin replication anew. The development of the virus requires several critical viral enzymes, including protease (PR), which is essential for the life-cycle of HIV, and reverse transcriptase (RT), which reverse transcribes the single-stranded viral RNA genome back to double stranded DNA copies. The drugs for HIV treatment therefore are often targeting at these enzymes, including several types of protease inhibitors and reverse transcriptase inhibitors. The drugs work by binding to the active sites of the targeting proteins to disable their functions. However, due to the high mutation rates of retroviruses under selective pressure of drugs, the enzymes can rapidly change and thus lead to drug resistance. Due to protein structures, not all mutations are equally important to resistant drugs. The complicated mutation patterns are thus difficult to interpret (Shafer, 2002) ; (Liu and Shafer, 2006) .
By sequencing viral strains in the drug-treatedpatient isolates, the genotypic data have been generated for two major viral enzymes: PR and RT. Currently the Stanford HIV Drug Resistance database (http://hivdb.stanford.edu) contains nearly all published HIV-1 PR and RT sequences, along with their quantified drug resistance assays. Drug resistance of an isolate is measured by IC50 (half maximal inhibitory concentration), which is the concentration of a drug required for 50% inhibition in vitro. Using these data, our goal is to infer genotype (protein) and phenotype (drug resistance) relationships.
Several statistical and machine learning methods have been attempted on these data to help predicting phenotypes from genotypes (Shafer, 2002) ; (Beerenwinkel, 2002) ; (Ravela et al., 2003) ; (Liu and Shafer, 2006) ; (Rhee et al., 2006) ; (Saigo et al., 2007) . However, prediction provides little insight on the genetic basis of drug resistance, and often their results are inconsistent when analyzing the same input data (Ravela et al., 2003) ; (Liu and Shafer 2006) . In recent years, advanced statistical methods have been developed to particularly study the genotype-phenotype relationships, including the BVP model (Zhang et al., 2010 ) and the GKRR model (Hinkley et al., 2011) . The BVP model is a Bayesian partitioning algorithm that recursively infers the dependence and conditional independence structures of mutations to drug resistance. BVP however requires pre-screening of a handful of amino acids that are likely to be associated with the phenotypes, and thus is not directly applicable to the original protein data of hundreds of amino acids. The GKRR model stands for generalized kernel ridge regression, which is a penalty-based regression method. Their approach can detect main and pairwise interaction of mutations in regression setting, but it is computationally prohibitive to detect higher order interactions. Penalty-based regression also may not produce consistent results in dependent data.
In this paper, we develop a new Bayesian algorithm to analyze the HIV-1 drug resistance data. The algorithm is called BEAM3 (Zhang, 2011) , which was originally developed for genome-wide disease association studies. Distinct from most existing approaches, BEAM3 has three main features: 1) it is computationally efficient and statistically powerful for detecting both marginal and joint associations of multiple variables in large datasets; 2) it automatically and sufficiently accounts for unknown strong dependence among variables, such that only the direct association with phenotypes are reported, while indirect associations are filtered to improve the mapping resolution; and 3) it outputs a detailed graphical structure of how variables interact and jointly affect phenotypes. Previous comprehensive simulation studies have shown that BEAM3 outperforms many existing popular methods (Zhang, 2011) . The datasets for disease association studies and HIV-1 drug resistance share similar properties. First, both studies involve genotypic data as predictors. Second, both studies identify genotype-phenotype relationships, with possibly complicated interactions. Third, in both studies, the genotype data are strongly correlated. We therefore believe that BEAM3 is suitable for the HIV-1 drug resistance analysis.
Below we briefly introduce the BEAM3 method and describe how it is applied to the HIV-1 drug resistance data. We then present the results of our analysis on PR and RT genes under a variety of drug treatments. Our method detected many strong associations and interactions between protein mutations and drug resistance, and we found highdegree of cross-resistance of mutations to various drugs of the same type. We further constructed interaction graphs for PR and RT. Our analysis suggested a threshold model of the genetic mechanism for HIV-1 drug resistance. We conclude with discussion of extensions of our method for HIV-1 drug resistance studies. (Rhee et al., 2006) , and thus represent high quality data. We also downloaded the genotype-treatment datasets for PR and RT genes, respectively, where isolates received antiretrovials before isolation and sequencing serve as cases, and untreated isolates serve as controls. The bulk datasets contain 44371 isolates (12510 cases) for PR and 43995 isolates (18567 cases) for RT.
MATERIAL AND METHODS

Datasets and Pre-processing
Each dataset contains two types of information per isolate: the IC50 value and the protein mutations relative to a reference sequence (consensus subtype B obtained by aligning untreated isolates). We first pre-processed the data to convert the IC50 values into binary values 0 and 1 indicating non-resistant and resistant status, respectively. The conversion is done at the intermediate threshold levels provided in Rhee et al. (2006) , i.e., we separated the isolates into cases and controls, where controls included isolates susceptible to drugs, and cases included isolates either moderately or stringently resistant to drugs. We further converted the protein data at each amino acid position to 0 and 1 corresponding to wild type and mutant, respectively, relative to the consensus.
The BEAM3 Framework
BEAM3 assumes two sets of input data X (genotypes) and Y (phenotypes). Let L denote the number of variables in X, i.e., X=(X 1 ,…,X L ). In our case, L corresponds to the number of amino acids in a protein sequence, and X i denotes the mutation status at the ith amino acid in all isolates. Let N denote the number of isolates, then X i is a N-dim vector of mutation indicators, and
Our method is a full Bayesian approach that partitions the L amino acids in X into two nonoverlapping classes. Let I=(I 1 ,…,I L ) denote the class memberships of the L amino acids, with I i =1 denoting that the ith amino acid is directly associated with drug resistance, and I i =0 denoting otherwise. Our task is then to learn from the data the best partition of the amino acids, and our targets of interest are those with indicators I i =1.
For notation simplicity, let X (0) and X (1) denote the collection of amino acids belonging to classes 0 and 1 (I i = 0 or 1), respectively. The full probability function can be expressed in the form:
Since we assume that class 0 amino acids X (0) are not directly associated with drug resistance (Y) given the directly associated class 1 amino acids X (1) , we can drop Y from Pr(X ,Y), and our model becomes
It is seen that both Pr(X) and Pr(Y) are invariant with respect to any partition of X, and hence our model is proportional to the ratio Pr(X (1) |Y)/Pr(X
). This ratio is essentially evaluating whether or not the partition X (1) is indeed related with Y in the conditional probabilistic sense compared to its marginal distribution Pr(X (1) ). In a Bayesian framework, the complexity of the probabilistic functions in both numerator and denominator of the ratio are accounted for by the priors of model parameters. Our method therefore can avoid overfitting the data, as the numerator function is more complex than the denominator function.
A Graphical Implementation
We next define the detailed probability functions Pr(X 
|Y) and Pr(X (1)
). In our case, the data are categorical, and thus a simple choice could be the probability functions of multinomial distributions. A naïve usage of multinomial distributions, however, is not efficient when the number of variables in X (1) is large relative to the sample size. This is because the model complexity of saturated multinomial distributions increases exponentially with respect to the size of X (1) . To reduce model complexity and thus improve the power of our method, we introduce an auxiliary variable G= (V, E) , where G is an undirected acyclic graph with nodes (V) representing a finer partition of amino acids in X (1) , and edges (E) connecting the nodes representing "interaction" (joint association) between sets of amino acids in X (1) . There are two major advantages provided by this additional graph variable G. First, the model complexity of Pr(X (1) |Y) can be drastically reduced relative to saturated models and thus improves power. Second, G represents an interaction graph for "causative" drug resistant mutations, which can be used for model interpretation and future hypothesis testing of genetic interactions towards drug resistance. As an example, if a graph G reconstructed from the data consists of nodes V={{3,6}, {7}, {9}, {11}} and edges E={{3,6}-{7}, {3,6}-{9}}, we can interpret the model as that amino acids at positions 3, 6, 7, 9, 11 are directly associated with drug resistance, while other positions are not. In addition, amino acids {3,6,7} are jointly associated with drug resistance, so are {3,6,9}. Amino acid {11} is marginally associated (independent of others), while {7} and {9} are conditionally independent given {3,6}.
We rewrite Pr(X
,G|Y), where the latter can be decomposed by chain rules as a product of marginal and conditional probability functions for nodes and edges in G. In particular,
where {u~v}E denotes the pairs of connected nodes u and v in the graph. We then specify each probabilistic function Pr(X v |Y) as the ratio between Pr(X v ,Y) and Pr(Y) by using multinomial distributions for each. We further integrate out multinomial parameters using Dirichlet priors. In similar ways, we rewrite Pr(X (1) ) as
which again utilizes a graphical structure, but the graph G* is different from G and is used to capture the dependence among amino acids in X (1) . Since Pr(X (1) ) is in the denominator in (2), we marginalize out G* to improve the convergence of our method.
For the priors of indicator vector I, we assign independent Bernoulli priors to each indicator variable I i , where the Bernoulli parameter is set at 0.05/L by default. For the priors of graph G, we assign a Pitman-Yor process prior (Pitman and Yor, 1997) to the number of nodes in the graph, and assign a Bernoulli prior to each edge between two nodes (for presence or absence of the edge) with default parameter 0.1. We further enforce that G is acyclic by letting the priors of cyclic graphs be 0.
Our final model is written as
based on which we infer G and I from the data by Markov Chain Monte Carlo (MCMC) algorithms. More details of (5) can be found in Zhang (2011).
Markov Chain Monte Carlo
Our algorithm starts from a random partition of amino acids and a random graph on X
. We update the membership variable I of each amino acid iteratively, and if the membership is changed, we further update graph G. At each step, we update I i conditioning on the other parameters (I -i ,G -i ), where the subscript "-i" indicates the corresponding variables excluding X i . Let I new denote the new partition variable with I -i fixed but I i =0 or 1. Let X (1) new denote the new set of variables in class 1, including all variables (excluding X i ) previously in X
(1) , and also include X i if I i =1. We sample the values of I i from the following marginalized probability function that is proportional to
Here, the marginalization is done over all possible graphs G that includes X i and the fixed subgraph G -i . After updating I i , and if its value is 1, we sample a new graph G new by adding X i to the subgraph G -i according to the probability function
,G*)
On the other hand, if the value of I i is 0, we simply remove X i from graph G. We repeat the above procedure until the algorithm converges, and then collect posterior samples of I and G. We exclude samples from the first few iterations as burn-in. Our method outputs two types of results. One is the posterior probability of association with drug resistance at each amino acid position. The probabilities are represented as a summation of two quantities: marginal association probability and joint association probability. Here, marginal association means that the amino acid is related with drug resistance independently of other amino acids, where joint association means the amino acid is "interacting" with other amino acids and they jointly affect drug resistance. We put a quotation mark on interaction because mathematical definition of interaction is not given in our context, and it is more appropriate to say joint association. The second type of results output by our method is a graphical structure of how amino acids "interact" to affect drug resistance, where "interactions" are represented by edges between nodes. For simplicity, we only output marginal posterior modes of nodes and edges.
RESULTS
Drug Resistant Positions
We ran our program on the 18 datasets of 11 PR and 7 RT drug treatments. Each dataset contains treatedpatient isolates of one drug. We first pre-processed the data as described in Methods, and we ran our program on each dataset for 100 burn-in iterations followed by 100 sampling iterations. Running time of the algorithm ranges from a few minutes to one hour, depending on the complexity of the true association structure in each dataset. The protein, the drug, and the number of cases and controls in each dataset are summarized in Table 1 . We output the posterior probabilities of each amino acid position associated with drug resistance. Using these probabilities, we first estimated the number of positions showing direct association with drug resistance by summing the posterior probabilities over all amino acids. Unlike conventional approaches, our method sufficiently accounts for variable dependence, and hence our estimates are accurate and reliable (Zhang 2011) . As shown in the last row of Table 1 , we observed fairly consistent results in PR gene. There are ~30 amino acids out of 99 in PR sequence that are associated with drug resistance for 6 different PR inhibitors.
DetectingInteractingMutationClustersinHIV-1DrugResistance The only exception is TPV, for which we estimated only 9.1 positions with direct association. This is likely due to its relatively smaller sample size. For RT gene, interestingly, we observed uniformly smaller number (~8) of associated positions than in PR gene, despite of the fact that there are more (~245) amino acids in the RT sequence (although there are 560 positions in RT, nearly all mutants are found between positions 40-240). In addition, our method suggested that most of the associated positions work together to jointly resist drugs.
We show in Figures 1 the position-specific association probabilities for drug resistance in PR. The drug resistant positions are strikingly consistent across 6 out of 7 PR inhibitors (except for TPV). The consistency of the detected positions is known as cross-resistance to multiple drugs (Rhee et al., 2006) . We further show in Figure 1 the heatmap of pairwise correlation between PR drugs calculated from their position-specific association probabilities. We observed in the hierarchical tree that 6 PR drugs (except for TPV) formed a main cluster, and within which (NFV, SQV, IDV, RTV) were more closely. The relationships, however, were likely a result of the sample size effects of the PR datasets, because TPR, ATV, and LPV have the smallest sample sizes among the 7 PR drugs.
We next show in Figure 2 the results for RT gene. Again, we observed strong cross-resistance patterns. Among the 11 RT drugs, 3 (DLV, EFV, NVP) are nonnucleoside RT inhibitors (NNRTI) shown at the bottom of Figure 2 , while the other 8 RT drugs are nucleoside RT inhibitors (NRTI). Interestingly, the 3 NNRTIs share a common crossresistance pattern that is quite different from the cross-resistance pattern of the 8 NRTIs. It is further observed that the posterior probabilities of D4T and AZT were slightly but consistently different from the other NRTIs. These results, together, suggested three different resistance patterns in RT drugs. The 3 clusters of RT drugs are also seen in the correlation heatmap in Figure 2 , in which FTC appeared to be an outlier due to its small sample size. In addition to the individual drug datasets, we have also run our method on the bulk genotype-treatment datasets for PR and RT. The results are shown in the bottom of Figures 1 and 2 , respectively. From the bulk datasets, we estimated that there are 29.7 amino acid positions in PR associated with drug resistance, which is similar to the numbers obtained from the individual PR drug datasets. In contrast, we estimated 32.4 drug resistant positions from the bulk RT dataset, much greater than those obtained from the individual RT drug datasets. The results from the bulk datasets also suggested that RT has greater diversity of drug resistance patterns than PR does.
Correlations and Interactions
We next evaluated the correlation and interaction of the mutation events across amino acids in each protein. Given the high-degree of cross-resistance for HIV-1 drugs of the same types, we focused on analyzing the bulk genotype-treatment datasets for PR and RT, respectively, which contained many more samples and thus provided more power.
As shown in Figure 3 (ab), both PR and RT demonstrated very strong local correlation of mutation events, with some distant correlations as well. The banded pattern of local correlation is due to the duplication and selection process of HIV-1 viruses. Given the strong correlation of mutation events, it is statistically challenging to pinpoint the precise positions of drug resisting mutations. Our method automatically accounts for strong correlation among variables, and thus is able to identify the true interacting locations for drug resistance. As shown in Figure 3 (cd), we highlighted some strong interaction hotspots between pairs of amino acids, including both local and distant interactions. Note that the distribution of interaction hotspots is very different from the distribution of strong correlations, suggesting that the interactions detected by our method are not confounded by correlation.
We further show in Figure 4 the interaction graphs reconstructed by our method. These graphs provide detailed landscapes of how amino acids work together to resist drugs. The graphs are reconstructed such that each node represents an amino acid position with total (marginal+interacting) posterior probability of drug resistance >0.3, and each edge represents an interaction with posterior probability >0.3. The threshold 0.3 is chosen such that the numbers of nodes included in the graph is close to the numbers (k) in Table 1 . To our best knowledge, previous analyses of these datasets have not revealed such detailed relationships. For PR gene (Figure 4a ), we observed two major interacting clusters. Interestingly, the two clusters are relatively symmetric. We draw the amino acid positions in two colors: red and green correspond to the left half (amino acids ) and the right half (amino acids of the protease sequence, respectively. In the left cluster in Figure 4(a) , there are many left-half (red) amino acids interacting with a few right-half (green) amino acids, whereas in the right cluster, we observed the opposite pattern: many right-half (green) amino acids are interacting with a few left-half (red) amino acids. The X-ray 3D structure of HIV-1 protease revealed that PR is DetectingInteractingMutationClustersinHIV-1DrugResistance composed of a homodimer, with each subunit consisting of 99 amino acids. It is thus plausible that the two clusters of interacting sites correspond to the contact sites on the 3D structure of the two subunits of HIV-1 protease. The subunits come together to form a tunnel, and the active site of the protease is located in its interior (Spinelli et al., 1991) . Two flexible flaps outside the tunnel move around to allow proteins to enter the tunnel. Mutations at the detected sites may have changed the way the tunnel opens and closes, which then lead to drug resistance.
For RT gene (Figure 4b ), we also draw the amino acid positions in two colors: red and green corresponding to the finger domain (amino acids ) and the palm domain (amino acids ) of HIV-1 reverse transcriptase, respectively. All associated mutations we found are within the finger and palm domains. We observed several strong drug-resistant interactions between the finger and palm domains, and also within the palm domain. Interpreting these interactions based on the current datasets, however, is difficult, because the HIV-1 reverse transcriptase is composed of a heterodimer: p66 and p51 (Rodgers et al., 1995) .
While the p66 subunit consists of the full set of 560 amino acids, the p51 subunit only consists of 450 of the 560 amino acids after post-translational modification. As a result, the two subunits serve different functions. While p66 is the catalytic subunit with DNA polymerase and RNase H activity, p51 is mainly responsible for stabilizing the p66 subunit. The mutations at the detected positions may affect the activity of either subunit, or both.
Significant Interactions and Effects
We finally used logistic regression to evaluate the effects and the statistical significance of the detected associations and interactions. We evaluated both main effects and pairwise interaction effects identified by our method. The regression terms are those with posterior probability >0.3 from the bulk datasets for PR and RT, respectively. To further measure model fitting, we calculated Akaike Information Criterion (AIC, Akaike, 1974) and Bayesian Information Criterion (BIC, DiCiccio et al. 1997 ) of the main effect only model and the main + pairwise interaction effect model. Table 2 : Amino acid positions with significant main and pairwise interaction effects in (a) protease and (b) reverse transcriptase, respectively. The terms are classified by their significance levels. The minus sign indicates that the term has negative effects to drug resistance. (c) shows the model fit using main effects only and main + interaction effect models. -13, -14, 24, 25, 31, 33, -36, -37, -38, -40, -42, 47, 49, 51, 55, -61, 62, -71, 74, 75, 77, 83, 85, 86, 89, -90, 91, -94, -99 (13,14) , (21, , 66, 70, 71, 76, -87, 91, 104, 107, 117, -122, 123, 152, -159, -163, 182, 185, 189, 191, -201, -205, 211, -215, 216 -(42,71), -(63,159), -(71,185), -(104,182), -(104,185), (159,163), -(182,185), -(182,191), -(185,191) As shown in Table 2 (a,b), in both PR and RT, we identified strong interaction effects between mutations at different positions. Most of the detected effects are highly significant (p-value < 0.001), because those terms are identified by our method with large posterior probabilities (>0.3). We further show in Table 2 (c) the comparison of the model fits between the main effect model and the main + interaction model. It is seen that the interaction model has much better (smaller) AIC and BIC values for both PR and RT. Combining all evidence we have shown, we believe that there are strong interactions among mutations at different positions in the protein sequence jointly resisting drugs. Interestingly, most interaction effects in the regression models are negative, suggesting that the effects of multiple mutations tend to be smaller than their additive values. This observation may indicate a threshold model for the genetic mechanism of drug resistance: once the joint effects of multiple mutations reached a threshold, it leads to a phenotypic change (such as disabling the protein's active sites and resisting drugs), where additional mutations contribute no more. We also observed several negative main effects in both PR and RT, indicating marginal drug susceptible positions.
CONCLUSIONS
We have introduced a novel Bayesian method to analyze the complex mutation patterns for drug resistance in HIV-1 protease and reverse transcriptase. The important mutations identified by our method agree with those reported in previous studies (Johnson et al., 2008) , but our results revealed stronger cross-resistance of the detected mutation sites, using posterior association probabilities, than by previous studies (Rhee et al, 2006) . In addition, we observed different groups of RT drugs that showed deviation of mutation patterns in drug resistance. The identified groups of drugs coincided with the NRTI and NNRTI drug categories, and within the NRTI drugs, D4T and AZT further showed slightly but consistently different mutation patterns from the others. The mutation patterns for cross-resistance as well as divergence to specific drugs revealed by our method can shed lights on the design of new antiretroviral drugs and on using genotypic drug resistance testing to select optimal therapy (Rhee et al 2006) . For example, combination of drugs with the least crossresistance may be identified to improve the effectiveness of HIV-1 drug treatment.
Using our method, we were able to reconstruct a sophisticated interaction graph delineating the detailed interaction relationships between amino DetectingInteractingMutationClustersinHIV-1DrugResistance acid positions in each protein sequence. From the reconstructed interaction graphs, we observed clusters of mutations at distant locations that work together to resist drug binding. The mutation sites within an interacting cluster are likely in close contact in the protein folding space that jointly resist drug binding. Our logistic regression analysis using the identified interaction models revealed that most identified interaction effects are statistically significant, but have negative effects on drug resistance. This observation may suggest a threshold model that multiple occurrence of mutations up to a threshold is needed to resist drug binding. In addition, the negative main effects estimated by our regression model also indicated positions that may increase HIV-1 susceptibility to drugs. Follow-up investigation of the directions and properties of specific mutants at the identified amino acid positions can help us truly understanding their genetic mechanisms underlying drug resistance. Molecular dynamics (MD) simulations (Zhang et al. 2010) can also be used to evaluate the molecular basis of how mutations interfere with drug binding.
Previous works using the genotype-phenotype data from Stanford HIVdb were mostly focusing on predicting drug resistance from the genotype information. The phenotype data were all measured in vitro. Due to the complex disease progression and pharmacokinetic factors, however, the phenotypes measured in vitro may not necessarily imply virologic failure in vivo (Shafer, 2002) . Also, predicting the failure of drug treatments does not in general help us understanding its genetic and molecular mechanisms, and provides little insights to the development of optimal therapies. Our analysis, in contrast, is not designed for predicting phenotypes, but for identifying important mutation sites and their interaction patterns that are directly influencing drug resistance. Given the observed strong correlation among mutations in PR and RT, precisely pinpointing the causative mutations from the genotype-phenotype data is an extremely challenging inference problem. Our method utilizes graphs to account for variable dependence. Extensive simulation studies (Zhang, 2011) have shown that our method is able to account for most complex dependence structures and is more powerful than existing methods to identify the true models underlying the data. Only until recently advanced statistical methods have been developed for analyzing the HIV-1 drug resistance data for detecting mutation interactions (Haq et al., 2009); Zhang et al., 2010) ; (Hinkley et al., 2011 ). Yet those methods do not sufficiently address the correlation problem, and thus have limitation in their abilities to find complex interactions.
Our analysis of the Stanford HIVdb datasets is still preliminary. Several complications have not been considered in our current model. For simplicity, we only considered mutation versus wild type at each amino acid position. An obvious extension of the analysis is to include the specific mutation types into our model. We can solve this problem by introducing a dummy variable for each type of mutants, and expanding the current datasets of L amino acids to L  p dummy variables, where p denotes the average number of different mutants per position. Such an extension is straightforward, although it requires further computing. Also, we only considered two categories of drug resistance levels in this study: susceptible versus intermediate to stringent resistance. Given that the basis function in our model is multinomial distribution, it is straightforward to extend the current model to include k levels of drug resistance. It is also possible to directly include the continuous IC50 values into our model by defining a continuous probability basis function. In addition, the bulk datasets we analyzed contain HIV-1 isolates from various studies of different drug treatments. It is thus possible that there are subpopulations in both treated and untreated samples. Population structure and possibly other confounding factors may bias our statistical analysis. A remedy is to perform isolate-matching (based on their genetic contents) between cases and controls before running our algorithm. Alternatively, we may design a hierarchical model for the drug resistance of different drugs, where each mutation can be classified as either cross-resistant or drug (or study) specific, depending on whether the distribution of the mutations agree across different drug treatments (or studies). Such an analysis will then directly reveal cross-resistant and drug-specific mutations interconnected in a hierarchal way for downstream use. Finally, HIV-1 integrase is another critical protein for the HIV development. It is desirable to further analyse the HIV-1 integrase drug resistance data if available.
In summary, we have demonstrated the potential of our method and the feasibility of reconstructing the complex structure of mutation patterns in HIV-1 drug resistance datasets. Further investigation of the growing Stanford HIVdb datasets and development of new advanced statistical methods are warranted for improving the potency of drugs to combat HIV resistance. Our method is also generally applicable to other studies for understanding the complex phenotype-genotype relationships, such as human complex disease studies and cancer studies.
